Comment on Predictive factors for a severe course of COVID-19 infection in Myasthenia gravis patients with an overall impact on myasthenic status and survival " by JakubíKová et al."

We read with interest the report by Jakubikova et al [1] on predictive factors affecting myasthenia gravis (MG) and survival in severe COVID-19 patients in two centers of the Czech Republic. Although the study was certainly conducted with good methodology, our careful reading raised some points of discussion. First, we were impressed by the number of patients enrolled. The authors should provide information regarding the global incidence of COVID-19 in the Czech Republic and the prevalence of MG in the 2 centers of Prague and Brno during the pandemic .